Corcept Therapeutics (NASDAQ: CORT) reported Q4 EPS of $0.01, $0.03 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $15 million versus the consensus estimate of $15.5 million.

GUIDANCE:

Corcept Therapeutics sees FY2016 revenue of $76-81 million, versus the consensus of $83.3 million.

For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.